Free Trial

CalciMedica (CALC) Competitors

CalciMedica logo
$3.17 -0.26 (-7.58%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$3.22 +0.06 (+1.74%)
As of 09/12/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CALC vs. IPHA, NLTX, BDTX, BIOA, FTLF, CGTX, MDWD, TIL, TVGN, and SXTC

Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Innate Pharma (IPHA), Neoleukin Therapeutics (NLTX), Black Diamond Therapeutics (BDTX), BioAge Labs (BIOA), FitLife Brands (FTLF), Cognition Therapeutics (CGTX), MediWound (MDWD), Instil Bio (TIL), Tevogen Bio (TVGN), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry.

CalciMedica vs. Its Competitors

Innate Pharma (NASDAQ:IPHA) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Innate Pharma presently has a consensus target price of $11.00, suggesting a potential upside of 450.00%. CalciMedica has a consensus target price of $16.00, suggesting a potential upside of 404.73%. Given Innate Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Innate Pharma is more favorable than CalciMedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innate Pharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
CalciMedica
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

0.2% of Innate Pharma shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 41.5% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Innate Pharma has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

In the previous week, Innate Pharma and Innate Pharma both had 3 articles in the media. Innate Pharma's average media sentiment score of 1.27 beat CalciMedica's score of 0.63 indicating that Innate Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Innate Pharma Positive
CalciMedica Positive

Innate Pharma's return on equity of 0.00% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Innate PharmaN/A N/A N/A
CalciMedica N/A -206.51%-103.81%

CalciMedica has lower revenue, but higher earnings than Innate Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innate Pharma$21.77M8.47-$53.53MN/AN/A
CalciMedicaN/AN/A-$13.70M-$1.60-1.98

Summary

Innate Pharma beats CalciMedica on 9 of the 12 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALC vs. The Competition

MetricCalciMedicaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$47.92M$3.20B$5.87B$10.13B
Dividend YieldN/A2.30%5.68%4.60%
P/E Ratio-1.9821.1774.5225.93
Price / SalesN/A436.80537.17192.28
Price / CashN/A46.6837.5660.44
Price / Book2.969.6112.166.29
Net Income-$13.70M-$53.29M$3.28B$270.77M
7 Day Performance2.92%0.28%0.87%3.88%
1 Month Performance33.76%5.73%4.96%4.88%
1 Year Performance-18.82%10.52%60.74%26.01%

CalciMedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALC
CalciMedica
2.4705 of 5 stars
$3.17
-7.6%
$16.00
+404.7%
-23.8%$47.92MN/A-1.9830Short Interest ↑
IPHA
Innate Pharma
3.0246 of 5 stars
$2.03
-0.5%
$11.00
+441.9%
-12.3%$187.13M$21.77M0.00220Positive News
Upcoming Earnings
NLTX
Neoleukin Therapeutics
N/A$19.45
-2.5%
N/A-50.2%$182.79MN/A-6.2590High Trading Volume
BDTX
Black Diamond Therapeutics
3.5548 of 5 stars
$3.17
+3.8%
$11.67
+268.6%
-44.4%$180.78MN/A13.8090Positive News
BIOA
BioAge Labs
0.2029 of 5 stars
$5.00
-1.8%
N/AN/A$179.25M$3.86M0.00N/APositive News
FTLF
FitLife Brands
4.3409 of 5 stars
$19.00
-0.7%
$23.00
+21.1%
+5.0%$178.36M$64.47M22.6120Positive News
CGTX
Cognition Therapeutics
2.8305 of 5 stars
$2.41
+0.5%
$2.83
+17.5%
+259.5%$178.29MN/A-3.6220Short Interest ↑
MDWD
MediWound
1.6307 of 5 stars
$16.34
-2.4%
$32.25
+97.4%
+1.3%$176.57M$19.86M-6.1980
TIL
Instil Bio
2.8753 of 5 stars
$25.71
-0.2%
$119.00
+362.9%
-48.1%$174.75MN/A-2.00410Analyst Forecast
Insider Trade
TVGN
Tevogen Bio
3.9047 of 5 stars
$0.88
+0.2%
$10.00
+1,035.1%
+75.8%$172.71MN/A0.003
SXTC
China SXT Pharmaceuticals
1.0634 of 5 stars
$1.48
-10.3%
N/A-62.5%$172.31M$1.74M0.0090Short Interest ↓

Related Companies and Tools


This page (NASDAQ:CALC) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners